Nebivolol (Bystolic) for hypertension

Medical Letter on Drugs and Therapeutics

Volumn 50, Issue 1281, 2008, Pages 17-19

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BISOPROLOL FUMARATE; BYSTOLIC; CARVEDILOL; ENALAPRIL MALEATE; FLUOXETINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LABETALOL; LISINOPRIL; LOSARTAN POTASSIUM; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; NEBIVOLOL; NIFEDIPINE; PENBUTOLOL; PINDOLOL; PLACEBO; PROPRANOLOL; TIMOLOL; TRIACYLGLYCEROL; BENZOPYRAN DERIVATIVE; ETHANOLAMINE DERIVATIVE; NEW DRUG;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER DYSFUNCTION; LOADING DRUG DOSE; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; METABOLISM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; DRUGS, INVESTIGATIONAL; ETHANOLAMINES; HUMANS; HYPERTENSION;

EID: 41649102909     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. LM Prisant. Nebivolol: Pharmacologic profile of an ultraselevtive, vasodilatory beta1-blocker. J Clin Pharmacol 2008; 48:225.
2. T Celik et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24:591.
3. R Weiss et al. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens 2007; 9:667.
4. E Saunders et al. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens 2007; 9:866.
5. I Czuriga et al. Comparison of the new cardioselective betablocker nebivolol with bisoprolol in hypertension: The nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc Drugs Ther 2003; 17:257.
6. L Van Nueten et al. Nebivolol vs. atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998; 12:135.
7. O Uhlir et al. Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest 1991; 3 Suppl. 1:107.
8. EA Rosei et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl 2003; 1:30.
9. LM Van Nueten et al. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens 1997; 11:813.
10. LM Van Bortel et al. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005; 18:1060.
11. L Van Nueten et al. Nebivolol versus nifedipine in the treatment of essential hypertension: A double-blind, randomized, comparative trial. Am J Ther 1998; 5:237.
12. A Mazza et al. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 2002; 11:182.
13. MD Flather et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215.
14. I Edes et al. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005; 7: 631.
15. Drug interactions. Med Lett Drugs Ther 2003; 45:46 .